Johnson & Johnson (JNJ) Stock Analysis

44.0/100
Sell ✓ Halal Healthcare
Price $289.30
Market Cap $687.89B
52-Week Change +46.35%

Is JNJ a good investment?

Johnson & Johnson (JNJ) has a Plutrex AI rating of 44.0/100 as of November 08, 2026, indicating a Sell consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Fortress balance sheet with D/E 0.44x (47.7% below industry average of 0.84x), $17.23B cash, and $20.59B annual FCF — the most conservative capital structure in the peer group, supporting 64 consecutive years of dividend growth (Dividend King) and providing M&A/buyback optionality without balance sheet stress. Main concern: Catastrophic and worsening valuation: P/E 41.90x on 4.27% next-year EPS growth (PEG 4.68x, up from 4.45x 14 days ago) — paying nearly 5x what growth justifies. Analyst consensus target fell from $285.82 to $284.62 while stock rose 4.7%, compressing implied upside from 8.3% to 3.0%. At a generous 2.0x PEG on 8.9% 5-year growth, justified P/E is ~17.8x, implying fair value ~$140-$165 before quality premium. Even with 35% fortress premium, entry zone is $215-$235 — requiring 15-20% pullback from current $276.22.

Investment Summary

Johnson & Johnson (JNJ) at $276.22 is a world-class business masquerading as an investable stock at current prices. The fundamental picture is bifurcated: exceptional quality (gross margin 67.7%, operating margin 25.7%, FCF $20.59B annually, D/E 0.44x) paired with catastrophic valuation (P/E 41.90x on 4.3% next-year EPS growth, PEG 4.68 — nearly 5x the fair-value threshold of 1.0). The stock has risen another 4.7% from $263.81 to $276.22 in 14 days, with the P/E expanding further from 40.02x to 41.90x (+4.7%) and PEG from 4.45x to 4.68x (+5.2%), while the analyst consensus target FELL from $285.82 to $284.62 (-$1.20). That means the stock moved TOWARD consensus while consensus itself retreated — the implied upside has narrowed from 8.3% to just 3.0%. News is genuinely positive: FDA accelerated approval of RYBREVANT FASPRO for HNSCC (first-mover in a decade-stagnant market), positive Phase 3 data for icotrokinra in psoriatic arthritis, and new Phase 2 nipocalimab data in Sjögren's disease confirm pipeline momentum. However, positive pipeline news cannot overcome a 41.9x P/E on sub-5% EPS growth. At a generous fair-value PEG of 2.0x and 8.9% 5-year growth, the implied justified P/E is ~17.8x — implying fair value near $140-$165. Even with a 35% fortress-quality premium, the entry zone remains $215-$235. The stock needs a 15-20% correction before the risk/reward becomes compelling.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
72/100
Growth Potential
18/100
Valuation
10/100
Profitability
88/100
Debt Management
85/100
Analyst Sentiment
42/100
Technical Momentum
38/100
Insider Confidence
50/100
News Sentiment
72/100

Fundamental Analysis

JNJ's fundamentals present a classic quality-at-wrong-price dilemma. PROFITABILITY: Gross margin 67.7% (vs industry 71.72% — 5.7% discount), operating margin 25.7% (vs industry 35.17% — 26.8% discount), net margin 16.2% (vs industry 15.92% — roughly at parity), ROE 20.0% (vs industry 22.94% — 12.7% discount). JNJ trails peers on gross and operating margins despite commanding a 28.6% PE premium. FINANCIAL HEALTH: D/E 0.44x (vs industry 0.84x — 47.7% more conservative), cash $17.23B, FCF $20.59B annually — extraordinary liquidity. GROWTH: Next-year EPS growth 4.27% (vs industry 92.06% — a staggering 2,055bps deficit), 5-year EPS growth 8.95% (vs industry 15.06% — 40.6% discount), revenue growth 5.9% (vs industry 15.6% — 62.2% discount). JNJ is structurally the worst grower in its peer group while trading at the highest PE premium. VALUATION: P/E 41.90x (vs industry 32.58x — 28.6% premium), PEG 4.68x (fair value = 1.0x, meaning investors pay $4.68 for every $1 of growth-justified value). Analyst consensus target $284.62 offers only 3.0% upside from current $276.22 — essentially no margin of safety. The YoY earnings collapse of -95.9% (massive litigation/spinoff charges) clouds earnings quality and makes the already-elevated P/E potentially understated on normalized earnings.

News Sentiment

Johnson & Johnson is making real medical progress — but Wall Street may be getting ahead of itself. The pharmaceutical giant is on a roll with regulatory wins and promising drug trial results, yet its soaring stock price tells a more complicated story. The biggest win: J&J just earned FDA accelerated approval for RYBREVANT FASPRO, a subcutaneous injection for a particularly aggressive form of head and neck cancer (HNSCC). This matters because there have been no major treatment advances in this disease for over a decade — giving J&J a rare first-mover advantage in a market hungry for new options. Meanwhile, the company announced that its experimental pill ICOTYDE delivered 'significant improvement' in a late-stage trial for psoriatic arthritis, a painful autoimmune condition affecting millions. If approved, it would compete in an underserved market with limited oral treatment options. J&J is also generating fresh Phase 2 data on nipocalimab for Sjögren's disease, expanding its autoimmune franchise. On the financial front, J&J reportedly holds one of the highest credit ratings of any U.S. company — a testament to its rock-solid balance sheet. The one shadow: a law firm investigation into investor claims (Pomerantz Law Firm alert) adds to the company's already-complex legal backdrop. The bottom line? J&J's pipeline is alive and productive. But with the stock trading at nearly 42 times earnings while growing profits at just 4% annually, the question isn't whether J&J is a great company — it clearly is. The question is whether this price makes sense.

Risk Assessment

PRIMARY RISK: Valuation compression. At P/E 41.90x on 4.27% EPS growth, any re-rating toward the industry average P/E of 32.58x (let alone fair value near 17-25x) would produce 20-40% drawdown. The stock needs either a 50%+ EPS growth acceleration (not forecasted) or a 40-50% price decline to reach fair value. SECONDARY RISK: Pipeline execution. RYBREVANT FASPRO, icotrokinra, and nipocalimab are promising but carry clinical/commercial uncertainty. If pipeline drugs underperform, the 8.9% five-year EPS growth estimate deteriorates, making the valuation even more indefensible. TERTIARY RISK: Litigation. Pomerantz Law Firm investor investigation (noted in headlines) adds to existing talc and opioid legal overhangs that have already contributed to -95.9% YoY earnings collapse. MITIGATION: JNJ's $20.59B FCF and $17.23B cash provide extraordinary legal liability absorption capacity. Dividend King status (64 consecutive years of growth) limits downside to ~$215-220 where yield becomes compelling (~2.5%). Do not short — the fortress balance sheet and pipeline create upside tail risk. Simply avoid new long positions above $235 and reduce/eliminate positions at current $276.22.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is JNJ a halal stock?

Yes, Johnson & Johnson (JNJ) is halal-compliant per AAOIFI standards as of the latest quarterly review.

What is Plutrex's AI rating for JNJ?

Johnson & Johnson (JNJ) has a Plutrex AI rating of 44.0/100 with a Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is JNJ a good investment?

According to Plutrex AI, JNJ has a Sell rating (44.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in JNJ?

US stocks like JNJ can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in JNJ?

Plutrex AI identifies the main risks for JNJ by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about JNJ

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open JNJ in ElBarake